1Peake N J, Khawaja K, Myers A,et al. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients:relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study[ J ]. Rheumatology ,2005,44( 11 ) :1383 - 1389.
3Tchetverikov I, Lohmander LS, Verzijl N, et al. MMP protein and activity levels in synovial fluid from patients with joint injury,inflammatory arthritis, and osteoarthritis [ J ]. Ann Rheum Dis, 2005,64 ( 5 ) : 694 - 698.
5Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six month after measurement, in patient with early rheumatoid arthritis [ J ]. Arthritis Rheumat,2000,43 (4) :852 - 858.
6Young Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers [ J ]. Arthritis Rheumat,2007,56 (10) : 3236 - 3247.
10Sylvia D, Nadine L, Roif R, et al. Association of a specific haplotype across the genes MMP-1 and MMP-3 with radiographic joint destruction in rheumatoid arthritis[ J ], Arthritis Res Ther,2004,6 (3) : 199 - 207.
二级参考文献60
1Klimiuk PA,Sierakowski S,Latosiewicz R,et al.Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histologieal variants of rheumatoid synovitis. Rheumatology (Oxford),2002,41:78-87.
2Yamanaka H,Matsuda Y,Tanaka M,et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement,in patients with early rheumatoid arthritis. Arthritis Rheum,2000,43:852-858.
3Cunnane G,Fitz-Gerald O,Beeton C,et al. Early joint erosions and serum levels of matrix metalloproteinases 1,matrix metalloproteinases 3,and tissue inhibitor of metalloproteinases 1 in rheumatoid athritis.Arthritis Rheum,2001,44:2263 -2274.
4Ishiguro N,Ito T,Obata K,et al. Determination of stromelysin-1,72 Kda type Ⅳ collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1),and TIMP-2 in synovial fluid and serum from patients with rheumatoidarthritis .J Rheumatol, 1996,23:1599-1604.
5Wolfe F,Sharp JT.Radiographic outcome of recent-onset rheumatoid arthritis:a 19-year study of radiographic progression.Arthritis Rheum,1998,41:1571-1582.
6Green MJ,Gough AK,Devlin J,et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology,2003,42:83-88.
7Posthumus,MD,Limburg PC,Westra J. Serum matrix metalloproteinase 3in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol,2000,27:2761-2768.
8Ribbens C,Andre B,Jaspar J.Matrix mettalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.J Rheumatol,2000,27:888-893.
9Zucker S,Hymovitz M,Conner C,et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tis-sues:clinical experimental applications.Ann NY Acad Sci, 1999,878:212-227.
10Okada Y.Proteinases and matrix degradation. In:Kelley WN,Ruddy S,Harris ED,eds.Textbook of rheumatology.6th ed. Philadelphia:WB Saunders,2000.55-72.
